Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epicutaneous Grass Pollen Immunotherapy
NCT00719511Phase 2Completed
- Sponsor
- University of Zurich
- Start
- Feb 2008
- Primary completion
- Nov 2009
- Modality
- Allergy Immunotherapy
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Oralair in allergic rhinitis (AR) (4 arms), sponsored by University of Zurich. Primary endpoint: Visual Analog Scale Symptom Score. Started Feb 2008; status: completed.
02
Drugs
Oralair
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT00719511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00719511.